News & Announcements

Weil Serves as Antitrust Counsel to Allergan in its Acquisition by AbbVie

Weil is serving as antitrust counsel to Allergan, a global pharmaceutical leader, in AbbVie’s proposed acquisition of Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion. The transaction is expected to close in 2020, subject to certain regulatory approvals and approval by Allergan's Shareholders.

Weil’s antitrust team includes global Head of Antitrust/Competition Steven Newborn, partners Ann Malester and Brianne Kucerik, counsel Vadim Brusser, and associates Natalie Hayes, Jonathan Goldsmith and Vivian Wang.